

MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:21:36 ON 04 MAR 2007

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:21:58 ON 04 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10801141.str

SAEED



chain nodes :
 7 10
 ring nodes :
 1 2 3 4 5 6
 ring/chain nodes :
 8 9
 chain bonds :
 2-8 5-7 8-9 9-10
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 2-8 8-9 9-10
 exact bonds :
 5-7
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L1 STRUCTURE UPLOADED

=> D

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

SAEED

=> S L1

SAMPLE SEARCH INITIATED 18:22:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3044 TO ITERATE

65.7% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 57571 TO 64189

PROJECTED ANSWERS: 12386 TO 15556

L2 50 SEA SSS SAM L1

=> S L1 FULL

FULL SEARCH INITIATED 18:23:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 62237 TO ITERATE

100.0% PROCESSED 62237 ITERATIONS

15206 ANSWERS

SEARCH TIME: 00.00.01

L3 15206 SEA SSS FUL L1

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.00

173.21

FILE 'CAPLUS' ENTERED AT 18:23:57 ON 04 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11

FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L3

L4 3879 L3

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

SAEED

	ENTRY	SESSION
FULL ESTIMATED COST	2.35	175.56

FILE 'REGISTRY' ENTERED AT 18:26:52 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3
DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\108011411.str



chain nodes :

7 10 14

ring nodes :

1 2 3 4 5 6 8 9 12 13

chain bonds :

2-8 5-7 9-10 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-12 12-13

exact/norm bonds :

2-8 8-9 8-13 9-10 9-12 12-13 12-14

exact bonds :

5-7

SAEED

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 8 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
12:Atom 13:Atom 14:CLASS

L5 STRUCTURE UPLOADED

=> D

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L5

SAMPLE SEARCH INITIATED 18:27:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2 TO 124

PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> S L5 FULL

FULL SEARCH INITIATED 18:27:18 FILE 'REGISTRY'

SAEED

FULL SCREEN SEARCH COMPLETED - 55 TO ITERATE

100.0% PROCESSED 55 ITERATIONS
SEARCH TIME: 00.00.01

13 ANSWERS

L7 13 SEA SSS FUL L5

=> FILE CAPLUS
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	347.66

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 18:27:23 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L7

L8 5 L7

=> D IBIB ABS HITSTR TOT

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:844227 CAPLUS

DOCUMENT NUMBER: 145:432850

TITLE: Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and

in Vivo Anti-Inflammatory Activity

AUTHOR(S): DiMauro, Erin F.; Newcomb, John; Nunes, Joseph J.; Bemis, Jean E.; Boucher, Christina; Buchanan, John

L.;

Buckner, William H.; Cee, Victor J.; Chai, Lilly; Deak, Holly L.; Epstein, Linda F.; Faust, Ted; Gallant, Paul; Geuns-Meyer, Stephanie D.; Gore, Anu; Gu, Yan; Henkle, Brad; Hodous, Brian L.; Hsieh, Faye; Huang, Xin; Kim, Joseph L.; Lee, Josie H.; Martin, Matthew W.; Masse, Craig E.; McGowan, David C.; Metz, Daniela; Mohn, Deanne; Morgenstern, Kurt A.; Oliveira-dos-Santos, Antonio; Patel, Vinod P.;

Powers,

David; Rose, Paul E.; Schneider, Stephen; Tomlinson, Susan A.; Tudor, Yan-Yan; Turci, Susan M.; Welcher, Andrew A.; White, Ryan D.; Zhao, Huilin; Zhu, Li;

Zhu,

CORPORATE SOURCE: Xiaotian Department of Medicinal Chemistry, Department of HTS and Molecular Pharmacology and Department of

Molecular

SOURCE: Structure, Cambridge, MA, 02139, USA Journal of Medicinal Chemistry (2006), 49(19),

5671-5686


CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


GI



AB The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Two optimized, orally bioavailable compds. exhibit antiinflammatory activity (ED50 of 22 and 11 mg/kg, resp.) in the anti-CD3-induced prodn. of interleukin-2 (IL-2) in mice.

IT 882676-01-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of aminoquinazolines as potent and orally bioavailable inhibitors of lymphocyte-specific kinase)

RN 882676-01-9 CAPLUS

CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[2-(methylamino)-6-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 861881-17-6P 913067-87-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoquinazolines as potent and orally bioavailable inhibitors of lymphocyte-specific kinase)

RN 861881-17-6 CAPLUS

CN 2-Azetidinone, 1-[2-amino-4-(trifluoromethyl)phenyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 913067-87-5 CAPLUS

CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:381241 CAPLUS

DOCUMENT NUMBER: 144:432828

TITLE: Heteroaryl-substituted alkyne compounds as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Chaffee, Stuart C.; Albrecht, Brian K.; Hodous, Brian L.; Martin, Matthew W.; McGowan, David C.; DiMauro, Erin F.; Reddy, Gade; Cee, Victor J.; Olivieri,

Philip

R.; Reed, Anthony; Romero, Karina

PATENT ASSIGNER(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 330 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044823	A2	20060427	WO 2005-US37299	20051017
WO 2006044823	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CM, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MW, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006217380	A1	20060928	US 2005-251490	20051014
PRIORITY APPLN. INFO.:				
			US 2004-620100P	P 20041018
			US 2005-251490	A 20051014

OTHER SOURCE(S):

MARPAT 144:432828

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to heteroaryl-substituted alkynes of formula I, which are protein kinase modulators. In compds. 1, W, X, Y, and Z are independently selected from N and (un)substituted C; R1 is (un)substituted amino, acyl, acyloxy, carboxylate, carbamoyl, thiocarbamoyl, etc.; and R2 is 5- to 8-membered monocyclic, 6- to 12-membered bicyclic, or 7- to 14-membered tricyclic ring system, optionally including 1-3 heteroatoms selected from O, N, and S; including stereoisomers, tautomers, solvates, salts, derivs., and prodrugs thereof. The invention also relates to the preparation of 1, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the prophylaxis and treatment of protein kinase-mediated diseases,

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
including inflammation, cancer and related conditions. Chlorination of 3-iodo-4-methylbenzoic acid and amidation with 3-trifluoromethylaniline gave benzamide II, which underwent coupling with 2-amino-5-ethynylpyrimidine (prepn. from 2-amino-5-iodopyrimidine and trimethylsilylacetylene is given) to give pyrimidinylalkyne III. Several compds. of the invention, e.g., III, express IC50 values of less than or equal to 10 μ M both for Tie-2 and Lck kinase.

IT 884604-15-3P, 5-[(2-Amino-5-pyrimidinyl)ethynyl]-N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-2-(methoxy)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-substituted alkynes as protein kinase modulators)


RN 884604-15-3 CAPLUS
CN Benzamide, 5-[(2-amino-5-pyrimidinyl)ethynyl]-N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ACCESSION NUMBER: 2006-343955 CAPLUS
DOCUMENT NUMBER: 144:390936
TITLE: Aryl nitrogen-containing bicyclic compounds and their preparation, pharmaceutical compositions, and protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases
INVENTOR(S): Patel, Vinod P.; Kim, Joseph L.; Geuna-Meyer, Stephanie D.; Chaffee, Stuart C.; Cee, Victor J.; Hodous, Brian L.; Bellon, Steven; Harmange, Jean-Christophe; Olivieri, Philip R.; Thaman, Maya C.;
Dimauro, Erin F.; Buchanan, John L.; McGowan, David C.; Albrecht, Brian K.; Deak, Holly L.; Bemis, Jean E.; White, Ryan; Martin, Matthew W.; Haggood, Gregory J.; Tempest, Paul A.; Masse, Craig E.; Buckner, William H.; Herberich, Bradley J.; Graceffa, Russell; Zhang, Dawei; Xu, Shimin; Sham, Kelvin; Rzaasa, Robert M.; Falsely, James Richard; Chakrabarti, Partha P.; Cao, Guo-Qiang; Tomlinson, Susan Ann; Pettus, Liping H.; Smith, Adrian Leonard; Parao, Nick A.; Liu, Gang; Demorin, Frenel P.; Tasker, Andrew; Reed, Anthony
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 876 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006039718	A2	20060413	WO 2005-US35873	20051003
WO 2006039718	A3	20060713		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GR, GU, HK, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2004-615535P	P 20041001
			US 2005-240590	A 20050930
OTHER SOURCE(S):			MARPAT 144:390936	
GI				

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The invention comprises a class of compds. of formula I useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. Compds. of formula I wherein
A1 and one of A2 and A3 are independently CR5 or N; B is a bond, CR5R6, CO, NR6, O, S, SO, or SO2; R1 is halo, haloalkyl, NO2, CN, H, NH2 and derivs., OH and derivs., SH and derivs., CHO and derivs., OC(O)R and derivs., CO2H and derivs., CONH2 and derivs., CSNH2 and derivs., NHCHO and derivs., NHC(S)H and derivs., NHCONH2 and derivs., NHCSNH2 and derivs., SO2H and derivs., SO2NH2 and derivs., etc.; R2, R4, and R5 are independently H, halo, haloalkyl, NO2, CN, OH and derivs., SH and derivs., NH2 and derivs., CHO and derivs., CO2H and derivs., CONH2 and derivs., NHCSNH2 and derivs., SO2H and derivs., SO2NH2 and derivs., NHC(S)H and derivs., (un)substituted C1-10 (hetero)alkyl, (un)substituted C2-10 alkynyl, (un)substituted C2-10 (hetero)alkynyl, (un)substituted 3- to 10-membered (hetero)cycloalkyl, (un)substituted 4- to 10-membered (hetero)cycloalkenyl, etc.; R3 is (un)substituted (un)saturated 5- to 8-membered (hetero)monocyclic, (un)substituted (un)saturated 6- to 12-membered (hetero)bicyclic, or (un)substituted (un)saturated 7- to 14-membered (hetero)tricyclic rings; R6 is H, (un)substituted C1-10 (hetero)alkyl, (un)substituted C2-10 (hetero)alkenyl, (un)substituted C2-10 (hetero)alkynyl, (un)substituted 3- to 10-membered (hetero)cycloalkyl, (un)substituted 4- to 10-membered (hetero)cycloalkenyl, and their stereoisomers, tautomers, solvates, pharmaceutically acceptable salts, derivs., and prodrugs thereof are claimed. Accordingly, the invention also comprises pharmaceutical compds. comprising the compds. of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compds. and compns. of the invention, and intermediates and processes useful for the preparation of compds. of the invention.

Example
compound II was prepared by boration of 3-iodo-4-methylbenzoic acid with bis(pinacolato)diboron; the resulting 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid was converted to the corresponding acid chloride, in situ, and reacted with 2-fluoro-5-

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
trifluoromethylbenzamide to give N-(2-fluoro-5-fluoromethylphenyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, which underwent cross-coupling with 6-bromo-N-methylquinazolin-2-amine to give compd. II. About 2000 invention compds. of formula I were prepd. by similar procedures. All the invention compds. were tested for their protein kinase inhibitory activity. Example compd. I along with many other invention compds. showed good inhibitory activity. From the HTRP assay, the IC50 values for inhibition of Tie-2 was dedd. to be less than or equal to 1 μ M for some of the invention compds. For the inhibition of Lck kinase enzyme, some of the exemplary compds. exhibited an av. IC50 value of 25 μ M or less and some invention compd. exhibited an IC50 value of 1 μ M or less, in the human HTRP assay. The invention compds. were also found to be active inhibitors of the VEGF kinase receptor. Furthermore, some of the invention compds. exhibited activities in the monocyte assay with IC50 values of 25 μ M or less. Various compds. of the invention have selective inhibitory activity for specific kinase receptor enzymes, including Tie-2, Lck, p38 and VEGFR/KDR. Accordingly, the compds. of the invention would be useful in therapy as antineoplastic agents, antiinflammatory agents, or to minimize deleterious effects of Tie-2, Lck, VEGF and/or p38.


IT 861881-17-6P 882676-01-9P 882676-02-0P
882676-14-4P 882676-15-5P 882676-16-6P
882676-66-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl nitrogen-containing bicyclic compds. and their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)

RN 861881-17-6 CAPLUS
CN 2-Azetidinone, 1-[2-amino-4-(trifluoromethyl)phenyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 882676-01-9 CAPLUS
CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[2-(methylamino)-6-quinazolinyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 882676-02-0 CAPLUS
 CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidiny)-5-(trifluoromethyl)phenyl]-4-methyl-3-[[2-(1-piperidinyl)ethyl]amino]-6-quinazolinyl- (9CI) (CA INDEX NAME)




RN 882676-14-4 CAPLUS
 CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidiny)-5-(trifluoromethyl)phenyl]-4-methyl-3-[[3-(4-morpholinyl)propyl]amino]-6-quinazolinyl- (9CI) (CA INDEX NAME)




RN 882676-15-5 CAPLUS
 CN Benzamide, 3-[2-[[3-(diethylamino)propyl]amino]-6-quinazolinyl]-N-[2-(3,3-dimethyl-2-oxo-1-azetidiny)-5-(trifluoromethyl)phenyl]-4-methyl- (9CI)


L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 (Reactant or reagent)
 (intermediate; prepn. of aryl nitrogen-contg. bicyclic compds. and their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)
 RN 861881-16-5 CAPLUS
 CN 2-Azetidinone, 3,3-dimethyl-1-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 882676-16-6 CAPLUS
 CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidiny)-5-(trifluoromethyl)phenyl]-4-methyl-3-[[3-(1-piperidinyl)propyl]amino]-6-quinazolinyl- (9CI) (CA INDEX NAME)



RN 882678-66-2 CAPLUS
 CN Benzamide, 5-(2-amino-6-quinazolinyl)-N-[2-(3,3-dimethyl-2-oxo-1-azetidiny)-5-(trifluoromethyl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




IT 861881-16-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005:696877 CAPLUS
 DOCUMENT NUMBER: 143:211847
 TITLE: Preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity
 INVENTOR(S): Potashman, Michele; Kim, Tae-Seong; Bellon, Steven; Booker, Shon; Cheng, Yuan; Kim, Joseph L.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Harmange, Jean-Christophe; Borg, George; Weiss, Matthew;
 Hodous, Brian L.; Graceffa, Russell; Buckner, William H.; Masse, Craig E.; Choquette, Deborah; Martin, Matthew W.; Germain, Julie; Di Pietro, Lucian V.; Chaffee, Stuart C.; Nunes, Joseph J.; Buchanan, John L.; Habgood, Gregory J.; McGowan, David C.; Whittington, Douglas A.
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 444 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070891	A2	20050804	WO 2005-US2326	20050124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2005206571	A1	20050804	AU 2005-206571	20050124
CA 2553423	A1	20050804	CA 2005-2553423	20050124
EP 1713484	A2	20061025	EP 2005-722533	20050124
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
US 2006241115	A1	20061026	US 2005-42634	20050124
NO 2006003693	A	20061023	NO 2006-3693	20060817
PRIORITY APPLN. INFO.:			US 2004-538691P	P 20040123
			WO 2005-US2326	W 20050124

OTHER SOURCE(S): MARPAT 143:211847
 GI

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



II

AB The title compds. I [R1XAYR; R = (un)substituted aryl, heterocyclyl, cycloalkyl, etc.; R1 = (un)substituted quinolinyl, quinoxalinyl, pyrimidinyl, etc.; A = (un)substituted naphthalenediyl, etc.; X = O, S, (un)substituted NH, CH2; Y = NHCO, CONH, etc.] which are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases,

were prepared E.g., a multi-step synthesis of II, starting from 6-hydroxy-2-naphthoic acid, was given. The compds. I showed inhibition

of Lck kinase, c-Met kinase, and VEGFR kinase at less than 10 μ M. The invention encompasses novel compds. I, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutically compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

IT 861875-02-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl substituted naphthalenes as inhibitors of


Lck,

VEGFR and/or HGF related activity)


RN 861875-02-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-6-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl)oxy]- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 861881-16-5P 861881-17-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of heteroaryl substituted naphthalenes as inhibitors of

Lck,

VEGFR and/or HGF related activity)

RN 861881-16-5 CAPLUS

CN 2-Azetidinone, 1-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 861881-17-6 CAPLUS

CN 2-Azetidinone, 1-[2-amino-4-(trifluoromethyl)phenyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:799552 CAPLUS

DOCUMENT NUMBER:

141:314019

TITLE:

Processes for production of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivatives via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide

INVENTOR(S):

Tanaka, Tatsuyoshi; Sugawara, Masanobu; Maeda, Hirofumi; Nishiyama, Akira; Yasohara, Yoshihiko; Nagashima, Nobuo

PATENT ASSIGNEE(S):

Keneka Corporation, Japan

SOURCE:

PCT Int. Appl., 69 pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083166	A1	20040930	WO 2004-JP3535	20040317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004199005	A1	20041007	US 2004-801141	20040316
CA 2515789	A1	20040930	CA 2004-2515789	20040317
EP 1604975	A1	20051214	EP 2004-721366	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007954	A	20060307	BR 2004-7954	20040317
PRIORITY APPLN. INFO.:				
			JP 2003-72358	A 20030317
			JP 2003-98452	A 20030401
			US 2003-462687P	P 20030415
			WO 2004-JP3535	W 20040317

OTHER SOURCE(S):

MARPAT 141:314019

GI

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention provides processes by which (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. (I; R4 = C1-12 alkyl, C6-12 aryl, C7-12 aralkyl) useful as intermediates of drugs, particularly,

cholesteryl ester transfer protein (CETP) inhibitor can be easily and simply produced from easily available starting materials. According to the invention, (S)-N-[4-(trifluoromethyl)phenyl]-3-hydroxypentanamide (II) is produced from easily available raw materials and converted into (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide (III) through (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone (IV). Further, (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. I are produced by reacting (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone with

a carbamic acid ester. Thus, 12.83 g 4-(trifluoromethyl)aniline was added dropwise to 10.0 g neat Me 3-oxopentanoate at 115°, stirred for 25 min, treated with 50 mL toluene, and heated under stirring for 12 h to give 11.22 g N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide (57%) which (1.30 g) was hydrogenated in the presence of 50.0 mg ((S)-BINAP)RuBr₂ in 20 mL MeOH/H₂O (10/1) at 60° and hydrogen pressure of 3.0 kg/cm² to give 1.23 g II (95%, 84.7% ee). Methanesulfonyl chloride (703 mg) was added dropwise to a solution of 1.07 g II and 621 mg Et₃N in 8 mL Et₃N at 0° over 10 min and stirred at the same temperature for 1 h to give 1.48 g crude

(S)-N-[4-(trifluoromethyl)phenyl]-3-[(methanesulfonyl)oxy]pentanamide (V) (97%). A solution of 1.346 g V in 2.7 mL CH₂Cl₂ and 10.8 mL DMF

was added dropwise to a suspension of 158.7 mg NaH in the same solvent mixture at room temperature over 15 min and stirred at room temperature for 1 h to give 996.3 mg crude IV (87% yield, 83.0% ee) which was purified by silica gel chromatog. (864 mg) and recrystd. from hexane to give 454.3 mg IV (47%,

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
100% ee). IV (420 mg) was dissolved in 7.0 mL MeOH at room temp., treated

with 28 wt.% NaOMe/MeOH (668 mg), and stirred at room temp. for 1 h to give 459 mg I (R4 = Me) (97%, 100% ee).

IT 765315-38-6P, (R)-3-Ethyl-1-[4-(trifluoromethyl)phenyl]azetidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs.

via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide)

RN 765315-38-6 CAPLUS

CN 2-Azetidinone, 3-ethyl-1-[4-(trifluoromethyl)phenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> FILE CAPLUS
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
30.58	378.24

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-3.90	-3.90

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 18:32:36 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> D

LB ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:844227 CAPLUS
DN 145:438580
TI Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors
of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity
AU DiMauro, Erin P.; Newcomb, John; Nunes, Joseph J.; Bemis, Jean E.;
Boucher, Christina; Buchanan, John L.; Buckner, William H.; Cee, Victor
J.; Chai, Lilly; Deak, Holly L.; Epstein, Linda P.; Faust, Ted; Gallant,
Paul; Geuna-Meyer, Stephanie D.; Gore, Anu; Gu, Yan; Henkle, Brad;
Hodous,
Brian L.; Haieh, Faye; Huang, Xin; Kim, Joseph L.; Lee, Josie H.; Martin,
Matthew W.; Masse, Craig E.; McGowan, David C.; Metz, Daniela; Mohn,
Deanna; Morgenstern, Kurt A.; Oliveira-dos-Santos, Antonio; Patel, Vinod
P.; Powers, David; Rose, Paul E.; Schneider, Stephen; Tomlinson, Susan
A.;
Tudor, Yan-Yan; Turci, Susan M.; Welcher, Andrew A.; White, Ryan D.;
Zhao,
Huilin; Zhu, Li; Zhu, Xiaotian
CS Department of Medicinal Chemistry, Department of HTS and Molecular
Pharmacology and Department of Molecular Structure, Cambridge, MA, 02139,
USA
SO Journal of Medicinal Chemistry (2006), 49(19), 5671-5686
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.65

379.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.90

FILE 'REGISTRY' ENTERED AT 18:33:28 ON 04 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\108011412.str




chain nodes :
7 10 12 13 14 15
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
8 9
chain bonds :
2-8 5-7 8-9 9-10 9-12 12-13 13-14 13-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-8 8-9 9-10 13-14 13-15
exact bonds :
5-7 9-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 8 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS

L9 STRUCTURE UPLOADED

=> D
L9 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L9

SAMPLE SEARCH INITIATED 18:33:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 73 TO ITERATE

100.0% PROCESSED 73 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 948 TO 1972

PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> S L9 FULL

FULL SEARCH INITIATED 18:33:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1706 TO ITERATE

100.0% PROCESSED 1706 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

L11 4 SEA SSS FUL L9

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

SAEED

FULL ESTIMATED COST	172.10	551.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'CAPLUS' ENTERED AT 18:34:10 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L11
L12 1 L11

=> D IBIB ABS HITSTR TOT

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:799552 CAPLUS

DOCUMENT NUMBER: 141:314019

TITLE: Processes for production of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivatives via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide

INVENTOR(S): Tanaka, Tateyoshi; Sugawara, Masanobu; Maeda, Hirofumi; Nishiyama, Akira; Yasohara, Yoshihiko;

PATENT ASSIGNEE(S): Kaneka Corporation, Japan

SOURCE: PCT Int. Appl., 69 pp.

CODEN: P1XXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083166	A1	20040930	WO 2004-JP3535	20040317
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004199005	A1	20041007	US 2004-801141	20040316
CA 2515789	A1	20040930	CA 2004-2515789	20040317
EP 1604975	A1	20051214	EP 2004-721366	20040317
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004007954	A	20060307	BR 2004-7954	20040317
PRIORITY APPLN. INFO.:			JP 2003-72358	A 20030317
			JP 2003-98452	A 20030401
			US 2003-462687P	P 20030415
			WO 2004-JP3535	W 20040317

OTHER SOURCE(S): MARPAT 141:314019

GI

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention provides processes by which (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. (I; R4 = C1-12 alkyl, C6-12 aryl, C7-12 aralkyl) useful as intermediates of drugs, particularly,

cholesterol ester transfer protein (CETP) inhibitor can be easily and simply produced from easily available starting materials. According to the invention, (S)-N-[4-(trifluoromethyl)phenyl]-3-hydroxypentanamide (II)

is produced from easily available raw materials and converted into (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide (III) through (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone (IV). Further, (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. I are produced by reacting (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone with

a carbamic acid ester. Thus, 12.83 g 4-(trifluoromethyl)aniline was added dropwise to 10.0 g neat Me 3-oxopentanoate at 115°, stirred for 25 min, treated with 50 mL toluene, and heated under stirring for 12 h to give 11.22 g N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide (57%) which (1.30 g) was hydrogenated in the presence of 50.0 mg ((S)-BINAP)RuBr₂ in 20 mL MeOH/H₂O (10/1) at 60° and hydrogen pressure of 3.0 kg/cm² to give 1.23 g II (95%, 84.7% ee). Methanesulfonyl chloride (703 mg) was added dropwise to a solution of 1.07 g II and 621 mg Et₃N in 8 mL Et₃N at 0° over 10 min and stirred at the same temperature for 1 h to give 1.48 g crude

(S)-N-[4-(trifluoromethyl)phenyl]-3-[(methanesulfonyl)oxy]pentanamide (V) (97%). A solution of 1.346 g V in 2.7 mL CH₂Cl₂ and 10.8 mL DMF was added dropwise to a suspension of 158.7 mg NaH in the same solvent mixture at room temperature over 15 min and stirred at room temperature for 1 h to give 996.3 mg crude IV (87% yield, 83.0% ee) which was purified by silica gel chromatog. (864 mg) and recrystd. from hexane to give 454.3 mg IV (47%.

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

100% ee). IV (420 mg) was dissolved in 7.0 mL MeOH at room temp., treated with 28 wt.% NaOMe/MeOH (668 mg), and stirred at room temp. for 1 h to give 459 mg I (R4 = Me) (97%, 100% ee).

IT 765315-35-3P, (S)-N-[4-(trifluoromethyl)phenyl]-3-hydroxypentanamide 765315-36-4P, (S)-N-[4-(trifluoromethyl)phenyl]-3-[(methanesulfonyl)oxy]pentanamide 765315-37-5P, (S)-N-[4-(trifluoromethyl)phenyl]-3-[(4-methylphenylsulfonyl)oxy]pentanamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide

derivs. via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide)

RN 765315-35-3 CAPLUS

CN Pentanamide, 3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765315-36-4 CAPLUS

CN Pentanamide, 3-[(methanesulfonyl)oxy]-N-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765315-37-5 CAPLUS

CN Pentanamide, 3-[[4-(4-methylphenyl)sulfonyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.21

558.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-4.68

STN INTERNATIONAL LOGOFF AT 18:35:17 ON 04 MAR 2007